Monday, 25 Sep 2017

You are here

8 September 2017: The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes trends in MTX use and outcomes, fibromyalgia as an inflammatory disorder, drugs that stop psoriasis pruritus, drugs that don't cause TB, cardiovascular risk and what Rheums think of ACR/EULAR criteria.

  1. 192 Chronic fatigue patient show high TGF-B,low resistin, 17 cytokines correlate with activity(CXCL*, GF, IL-4, IL5, IL7, IL13, IL17F, several growth factors. https://buff.ly/2xa8A8k 
  2. Between 2004-2014, MTX use increased (40% to 64%) and biologic use increased (from to1.7% to 27%), but the rate of ortho hip and knee surgery dropped (72 to 51/1000pts in 2014) https://t.co/IE72n2YMPB
  3. Optimal MTX dosing in early #RA patients (≥10mg/wk w/in 3 mos and ≥20mg/wk @6mo) improves clinical & functional but not Xray outcomes https://t.co/dJQjFrub4Q
  4. A review of 230 SLE patients, 95 had both abnormal protein-creatinine ratio (PCR) AND a 24 Hr Protein measures; serial assessments showed PCR had insufficient accuracy vs 24hr-Prot measures https://t.co/UjtoRagWAF
  5. Base on claims data, prevalence of RA increased over 10 yr period; RA found in 1.28-1.36 million adults (or roughly 0.5%) by 2014 https://t.co/t5GwPsifIC
  6. Psoriasis pruritus seen in >80%; metaanalysis 13 trials shows Anti Il-17, JAK inhib, ADA, apremilast reduce pruritus https://t.co/KXbZxLizD0 
  7. Despite the FDA requiring TB testing for IL-17 inhibitors; no reported TB cases in 1st Yr RCTs and in vitro studies show no mTB reactivation with IL17inhibition  https://t.co/7A7fRUyaLN
  8. 167 RA patients that were serially assessed over 2 yrs; only BMD loss by DXA predicted Xray damage @ 12 & 24 mos; NOT DAS, RF, CCP, or ESR https://t.co/u6D6nJdKvx
  9. Study of 153K RA patients, 23% had Anemia,and review of their drugs found that anemia was only improved by tocilizumab, not with Tofa, DMARDs, other biologics. https://t.co/UY0DgU2usb
  10. New Recommendations on Biosimilar Use   
  11. Rheumatoid Arthritis Augments Cardiovascular Risk   
  12. Increasing Deaths and Breaking Bad with Fentanyl   
  13. Do Rheumatologists Use ACR/EULAR Guidance on Rheumatoid Arthritis? “Live Vote” Results   
  14. Hugo E. Jasin, MD (1933-2017)   
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

22 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses survey results on membranous nephritis and patient perceptions of steroids, nonadherence, celebrity arthritis and IgG4 treatment.

CDC: 40% of U.S Adults Claim to Have Arthritis

The CDC has reported its 2013 and 2014 prevalence statistics for arthritis and other chronic medical conditions affecting U.S. adults aged ≥18 years. Data is drawn from the ongoing Behavioral Risk Factor Surveillance System (BRFSS), a state-based, telephone survey of noninstitutionalized adults. Data herein is self-reported arthritis (OA, RA, Gout, FM) and is quantified by state and metropolitan areas.

15 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.

Why Rheumatologists Should Do Better Vaccinating this Flu Season

It is well known that influenza infection is more common in patients with rheumatologic diseases. Blumentals et al. showed that patients with rheumatoid arthritis are at increased risk for influenza regardless of DMARD/biologic use and may have a 2.75-fold increased incidence of related complications (https://buff.ly/2gYNTSz).

1 September 2017: The RheumNow Week in Review

This week's report includes new data on IL-1 inhibition and protection from CV events and lung cancer, baricitinib given a reprieve, and features on infections: HBV, shingles and mortality of septic arthritis.